| Drug Name |
Liothyronine |
| Drug ID |
BADD_D01296 |
| Description |
Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine.[T457] The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.[L5578] |
| Indications and Usage |
Liothyronine is officially approved for the following indications:
- Replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism.
- As an adjunct therapy to surgery and radioiodine in the management of thyroid cancer.
- As a diagnostic agent in suppression tests for mild hyperthyroidism or thyroid gland autonomy.[FDA label]
In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.[T457]
The lack of liothyronine can be presented as a pale and puffy face, coarse, brittle hair, dry skin, croaky voice and constipation as well as irregular periods, drowsiness, and lethargy.[T457]
Liothyronine should never be used in the suppression of benign nodules and nontoxic diffuse goiter in iodine-sufficient patients nor in the treatment of hyperthyroidism during the recovery phase of subacute thyroiditis.[FDA label] |
| Marketing Status |
approved; vet_approved |
| ATC Code |
H03AA02 |
| DrugBank ID |
DB00279
|
| KEGG ID |
D08128
|
| MeSH ID |
D014284
|
| PubChem ID |
5920
|
| TTD Drug ID |
D0S6JG
|
| NDC Product Code |
81955-0009 |
| UNII |
06LU7C9H1V
|
| Synonyms |
Triiodothyronine | T3 Thyroid Hormone | Thyroid Hormone, T3 | Liothyronine | 3,3',5-Triiodothyronine | Liothyronine Sodium | Cytomel |
